Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Shares Outstanding (2016 - 2025)

Marimed (MRMD) has disclosed Shares Outstanding for 15 consecutive years, with $396.9 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 4.05% to $396.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $396.9 million through Dec 2025, up 4.05% year-over-year, with the annual reading at $396.9 million for FY2025, 4.05% up from the prior year.
  • Shares Outstanding for Q4 2025 was $396.9 million at Marimed, up from $394.5 million in the prior quarter.
  • The five-year high for Shares Outstanding was $396.9 million in Q4 2025, with the low at $322.5 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $363.0 million, with a median of $375.1 million recorded in 2023.
  • The sharpest move saw Shares Outstanding plummeted 100.0% in 2023, then soared 7471845.59% in 2024.
  • Over 5 years, Shares Outstanding stood at $331.5 million in 2021, then grew by 2.99% to $341.5 million in 2022, then rose by 9.85% to $375.1 million in 2023, then rose by 1.69% to $381.5 million in 2024, then rose by 4.05% to $396.9 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $396.9 million, $394.5 million, and $392.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.